https://repositorio.uca.edu.ar/handle/123456789/655 2026-07-11T15:13:31Z 2026-07-11T15:13:31Z Crispo, James A. G. Farhat, Nawal Fortin, Yannick Pérez Lloret, Santiago Sikora, Lindsey Morgan, Rebecca L. Habash, Mara Gogna, Priyanka Shannon E. Kelly Elliott, Jesse Kohen, Dafna E. Bjerre, Lise M. Mattison, Donald R. Hessian, Renée C. Willis, Allison W. Krewski, Daniel https://repositorio.uca.edu.ar/handle/123456789/22055 2026-07-03T07:01:12Z 2024-01-01T00:00:00Z

Título: Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease Autor: Crispo, James A. G.; Farhat, Nawal; Fortin, Yannick; Pérez Lloret, Santiago; Sikora, Lindsey; Morgan, Rebecca L.; Habash, Mara; Gogna, Priyanka; Shannon E. Kelly; Elliott, Jesse; Kohen, Dafna E.; Bjerre, Lise M.; Mattison, Donald R.; Hessian, Renée C.; Willis, Allison W.; Krewski, Daniel Resumen: Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson’s disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case–control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.

2024-01-01T00:00:00Z Pérez Lloret, Santiago Enet, Alejandro Gonzalez Aleman, Gabriela https://repositorio.uca.edu.ar/handle/123456789/19079 2024-11-25T18:19:59Z 2024-01-01T00:00:00Z

Título: Tools for data analysis Autor: Pérez Lloret, Santiago; Enet, Alejandro; Gonzalez Aleman, Gabriela Resumen: What are statistics Good for in human research studies? Studies conducted on human beings may have different objectives and designs, but they all share some common principles. 1 We outline these principles as a cycle, shown in Figure 1. The first step is to obtain a sample from a population. A population is a group of human beings sharing one or more characteristics. In medical research, researchers usually define populations following a disease or a condition. Obtaining the sample is called “sampling”. 2 Researchers will then discuss the study with the potential participants. They will be part of the study sample if they accept to participate and fulfill all inclusion and exclusion criteria. Investigators will perform a series of procedures and assessments and may apply an intervention to the sample of participants. For example, a treatment may be used, and its effects on Parkinson’s Disease motor symptoms may be recorded. Notably, study results only represent the effects of the intervention on the sample of participants. However, researchers are generally interested in “extrapolating” these results to the target population. The “statistical inference” procedure allows for performing such extrapolations. 3 Statistics is the science of collecting, analyzing, and describing data to conclude a particular phenomenon based on a relatively limited sample material. 3 It employs mathematical and probabilistic tools to develop methods and models for data analysis...

2024-01-01T00:00:00Z Lissoni, Paolo Porro, Giorgio Messina, Giusy Galli, Carla Di Fede, Giuseppe Valentini, Agnese Simoes-e-Silva, Ana Cristina Cardinali, Daniel Pedro https://repositorio.uca.edu.ar/handle/123456789/13686 2022-03-26T05:01:11Z 2021-01-01T00:00:00Z

Título: A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care Autor: Lissoni, Paolo; Porro, Giorgio; Messina, Giusy; Galli, Carla; Di Fede, Giuseppe; Valentini, Agnese; Simoes-e-Silva, Ana Cristina; Cardinali, Daniel Pedro Resumen: Abstract: The recent advances in the investigation of tumour biology have demonstrated that the human body may produce several molecules provided by a natural anticancer activity without any toxicity, in particular the pineal hormones melatonin (MLT), 5-methoxytryptamine (5-MTT) and pinealine, the endogenous cannabinoids, oxytocin, and angiotensin 1-7 (Ang 1-7). Unfortunately, despite their well confirmed anticancer and non-toxic properties, very few clinical studies have been performed in an attempt to evaluate the potential therapeutic efficacy of the endogenous human anticancer molecules in the treatment of cancer patients, at least of those eligible for the only palliative therapy. Moreover, most studies have been generally limited to the use of the only pineal MLT. The present preliminary study was carried out to evaluate the anticancer efficacy of an oral administration of MLT (100 mg in the dark period) in association with 5-MTT (10 mg in the light period), the cannabinoid agent cannabidiol (CBD) ( 10 mg twice/day) and Ang 1-7 (0.5 mg/twice day) in a group of 14 untreatable advanced or metastatic cancer patients. The clinical response consisted of partial response (PR) in 2/14 (14%), and stable disease (SD) in 8/14 (57%). Then, a disease control (PR + SD) was achieved in 10/14 (71%), whereas the remaining 4/14 (29%) had a progressive disease. Moreover, disease control was associated with a significant increase in lymphocyte-to-monocyte ratio (LMR), by showing that the control of the neoplastic growth is mediated at least in part by an improvement in the antitumor immune status of cancer patients.The treatment was well tolerated in all patients, and in particular no important decline in blood pressure values occurred. On the contrary, a clear improvement in asthenia was obtained in 8/10 (80%) patients with important asthenia prior to study. This preliminary study may suggest that after the failure of the common standard anticancer therapies, the administration of the main endogenous anticancer neuroendocrine molecules, firstly MLT and Ang 1-7, could constitute an alternative approach to cancer patients instead of the simple best supportive care alone.

2021-01-01T00:00:00Z Lissoni, Paolo Porta, Enrica Rovelli, Franco Messina, Giusy Lissoni, Arianna Porro, Giorgio Porro, Davide Di Fede, Giuseppe Monzon, Alejandra Sassola, Andrea Cardinali, Daniel Pedro https://repositorio.uca.edu.ar/handle/123456789/13684 2022-03-26T05:00:56Z 2021-01-01T00:00:00Z

Título: A preliminary study of low-dose angiotensin 1-7 plus the pineal hormone melatonin in the treatment of human systemic diseases other than cancer and autoimmune pathologies Autor: Lissoni, Paolo; Porta, Enrica; Rovelli, Franco; Messina, Giusy; Lissoni, Arianna; Porro, Giorgio; Porro, Davide; Di Fede, Giuseppe; Monzon, Alejandra; Sassola, Andrea; Cardinali, Daniel Pedro Resumen: Abstract: The recent advances of the psychoneuroimmunology have demonstrated the existence of a physiological anti-inflammatory antitumor neuroendocrine axis, mainly constituted by the pineal gland through its indole hormone melatonin (MLT) and the ACE2-angiotensin 1-7 (Ang 1-7) system. Moreover, most human systemic diseases, including cancer, autoimmunity, metabolic, cardiovascular, and neurodegenerative pathologies, have appeared to be characterized by an endogenous deficiency in the functionless of the pineal gland and ACEACE2 system. Therefore, the exogenous correction of MLT and Ang 1-7 deficiency could improve the clinical control of human systemic diseases. On these bases, a preliminary study of MLT plus Ang 1-7 was planned in patients suffering from systemic alterations other than cancer and autoimmunity. The study included 33 consecutive patients, whose pathologies were, as follows: cardiovascular pathologies: 9; pulmonary diseases: 7; metabolic syndrome: 7; neurodegenerative pathologies: 10. Both Ang 1-7 and MLT were given orally, at a dose of 0.5 mg/day in the morning for Ang 1-7, and at a dose of 10 mg/day in the evening for MLT. The treatment was well tolerated in all patients, and no-therapy related toxicity occurred. On the contrary, most patients experienced a relief of anxiety and asthenia, and an improvement in both mood and quality of sleep. Moreover, most patients referred an increased diuresis. Blood pressure values progressively became within the normal range in hypertensive patients. On the same way, glucose and cholesterol levels progressively decrease on therapy in diabetic and hypercholesterolemic patients, respectively. Patients with pulmonary disturbance referred an important enhancement in the expectoration, with a following improvement in the respiratory symptomatology. Finally, an apparent improvement in cognitive and motor functions was achieved in patients with neurodegenerative pathologies. These preliminary results would suggest a future medical possibility to treat the human systemicdiseases by simply correcting their endogenous neuroendocrine deficiencies, mainly those involving the functions of the pineal gland and ACE2-Ang1-7 system.

2021-01-01T00:00:00Z